Cellenkos Receives FDA Clearance for CK0802 Phase 1b/2a Trial in Steroid-Refractory GVHD

Key Takeaways

• FDA cleared Cellenkos’ IND application for CK0802, a first-in-class off-the-shelf regulatory T cell therapy for steroid-refractory GVHD
• Phase 1b/2a multicenter trial will evaluate safety and preliminary efficacy in patients who haven’t responded to standard steroid treatment
• CK0802 represents a potential breakthrough for GVHD patients with limited treatment options beyond conventional immunosuppressive therapy

---

Cellenkos, Inc. announced May 4, 2026, that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to begin a Phase 1b/2a clinical trial of CK0802 in patients with steroid-refractory graft-versus-host disease (GVHD).

The Houston-based clinical-stage biotechnology company specializes in developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies. CK0802 represents a first-in-class, off-the-shelf Treg therapy designed specifically for patients whose GVHD has not responded to standard steroid treatment.

Understanding Steroid-Refractory GVHD

Graft-versus-host disease occurs when transplanted immune cells attack the recipient’s healthy tissues, commonly affecting patients who receive bone marrow or stem cell transplants. When patients don’t respond to corticosteroids—the standard first-line treatment—their condition becomes steroid-refractory, leaving limited therapeutic options.

The upcoming multicenter, open-label study will focus on evaluating both the safety profile and preliminary efficacy of CK0802 in this challenging patient population. Regulatory T cells play a crucial role in immune system regulation, and Cellenkos’ approach aims to harness these cells’ natural ability to suppress excessive immune responses.

Market Impact and Innovation

The FDA clearance positions Cellenkos to advance a potentially transformative therapy in the immunology space. Off-the-shelf cell therapies offer significant advantages over patient-specific treatments, including reduced manufacturing time and broader accessibility.

Cellenkos’ tissue-targeted approach represents an evolution in Treg therapy development, potentially offering more precise treatment compared to systemic immunosuppression. The company’s focus on allogeneic therapies could address scalability challenges that have historically limited cell therapy adoption.

The Phase 1b/2a trial design will provide critical data on dosing, safety parameters, and early efficacy signals that will inform future development decisions and potential regulatory pathways for CK0802.

---

Frequently Asked Questions

What does this FDA clearance mean for GVHD patients?

The FDA clearance allows Cellenkos to begin testing CK0802 in patients whose GVHD hasn’t responded to steroids, potentially offering a new treatment option for this difficult-to-treat condition.

When will CK0802 be available to patients?

CK0802 is entering Phase 1b/2a trials, meaning it’s still in early clinical development. If successful, the therapy would need to complete additional trials and receive full FDA approval before becoming commercially available.

How does CK0802 differ from current GVHD treatments?

CK0802 is a first-in-class, off-the-shelf regulatory T cell therapy that aims to precisely target immune responses, potentially offering advantages over current broad immunosuppressive treatments used for steroid-refractory GVHD.